Report of an International Workshop to Standardize Response Criteria for Non-Hodgkin's Lymphomas

American Society of Clinical Oncology (ASCO) - Tập 17 Số 4 - Trang 1244-1244 - 1999
Bruce D. Cheson1, Sandra J. Horning1, B Coiffier1, Margaret A. Shipp1, Richard I. Fisher1, Joseph M. Connors1, Tim Lister1, Julie M. Vose1,2, Antonio J Grillo-López1, Anton Hagenbeek1, Fernando Cabanillas1, Donald Klippensten1, Wolfgang Hiddemann1, Ronald A. Castellino1, Nancy L. Harris1, Jamés O. Armitage1,2, William Carter1, Richard T. Hoppe1, George P. Canellos1
1From the National Cancer Institute, Bethesda, MD; Stanford University, Palo Alto, CA; Centre Hospitalier Lyon-Sud, Lyon, France; Dana-Farber Cancer Institute, Boston, MA; Loyola University, Maywood, IL; British Columbia Cancer Agency, Vancouver, British Columbia, Canada; St. Bartholomew's Hospital, London, England; University of Nebraska, Omaha, NE; IDEC Corporation, San Diego, CA; Universiteit Utrecht, Utrecht, the Netherlands; M.D. Anderson Cancer Center, Houston, TX; Roswell Park Cancer Institute,...
2Oncology/Hematology

Tóm tắt

ABSTRACT: Standardized guidelines for response assessment are needed to ensure comparability among clinical trials in non-Hodgkin's lymphomas (NHL). To achieve this, two meetings were convened among United States and international lymphoma experts representing medical hematology/oncology, radiology, radiation oncology, and pathology to review currently used response definitions and to develop a uniform set of criteria for assessing response in clinical trials. The criteria that were developed include anatomic definitions of response, with normal lymph node size after treatment of 1.5 cm in the longest transverse diameter by computer-assisted tomography scan. A designation of complete response/unconfirmed was adopted to include patients with a greater than 75% reduction in tumor size after therapy but with a residual mass, to include patients—especially those with large-cell NHL—who may not have residual disease. Single-photon emission computed tomography gallium scans are encouraged as a valuable adjunct to assessment of patients with large-cell NHL, but such scans require appropriate expertise. Flow cytometric, cytogenetic, and molecular studies are not currently included in response definitions. Response rates may be the most important objective in phase II trials where the activity of a new agent is important and may provide support for approval by regulatory agencies. However, the goals of most phase III trials are to identify therapies that will prolong the progression-free survival, if not the overall survival, of the treated patients. We hope that these guidelines will serve to improve communication among investigators and comparability among clinical trials until clinically relevant laboratory and imaging studies are identified and become more widely available.

Từ khóa


Tài liệu tham khảo

10.1002/ajh.2830290307

10.1182/blood.V87.12.4990.bloodjournal87124990

10.1200/JCO.1990.8.5.813

10.1200/JCO.1989.7.11.1630

Therasse P, Eisenhauer E, Wanders J, et al: Evaluation of response to treatment in solid tumors. Can the methodology be harmonized and simplified? Ann Oncol 2:25,1998, (suppl) (abstr)

10.1200/JCO.1987.5.10.1670

10.1200/JCO.1988.6.3.559

Grillo-López AJ, Horning S, Cheson B, et al: Development of response criteria (RC) for low-grade or follicular lymphomas (LG/FNHL) and application in a 166 patient study. Exper Hematol 25:732,1997, (abstr 17)

10.1200/JCO.1996.14.9.2427

10.1200/JCO.1996.14.9.2431

10.1002/ajh.2830030201

10.1002/1097-0142(197807)42:1<88::AID-CNCR2820420115>3.0.CO;2-U

10.1148/radiology.180.2.2068292

10.1148/radiographics.11.3.1852937

10.2214/ajr.144.2.261

Hopper KD, Kasales CJ, Van Slyke MA, et al: Analysis of interobserver and intraobserver variability in CT tumor measurements. AJR Am J Roentgenol 187:851,1996-854,

10.2214/ajr.150.4.771

10.1148/radiology.191.3.8184067

10.1148/radiology.192.3.8058923

10.2214/ajr.142.6.1095

10.1097/00004728-198208000-00025

10.1002/mpo.2950100502

10.1002/1097-0142(19850201)55:3<620::AID-CNCR2820550324>3.0.CO;2-7

10.1200/JCO.1988.6.12.1832

10.1200/JCO.1991.9.1.25

10.1200/JCO.1993.11.5.943

10.1056/NEJM199312093292404

10.1200/JCO.1990.8.2.248

10.1182/blood.V82.12.3564.3564

10.1200/JCO.1989.7.8.1018

10.1200/JCO.1992.10.11.1690

10.1177/028418518702800202

10.2214/ajr.138.2.329

Shipp MA, Ambinder RF, Appelbaum FR, et al: NCCN preliminary non–Hodgkin's lymphoma practice guidelines. Oncology (Huntingt) 11:281,1997-346,

10.1200/JCO.1991.9.7.1196

10.1200/JCO.1996.14.9.2473

10.1016/0002-9343(80)90256-9

10.1200/JCO.1993.11.11.2273

10.1002/1097-0142(19880615)61:12<2439::AID-CNCR2820611208>3.0.CO;2-Q

10.1200/JCO.1990.8.12.1966

10.1200/JCO.1997.15.4.1631

10.1200/JCO.1995.13.4.942

Römer W, Hahauske A-R, Zieger S, et al: Positron-emission tomography in non-Hodgkin's lymphoma: Assessment of chemotherapy with fluorodeoxyglucose. Blood 91:4464,1998-4471,

10.1023/A:1008249700499

10.1182/blood.V78.3.728.728

10.1200/JCO.1997.15.5.1754

Moog F, Bangerter M, Kotzerke J, et al: 18-F-fluorodeoxyglucose-positron emission tomography as a new approach to detect lymphomatous bone marrow. Blood 16:603,1998-609,

10.1182/blood.V91.9.3340

Thông tin
Thông tin xuất bản

American Society of Clinical Oncology (ASCO)

Tập 17 Số 4

1244-1244

Thông tin tác giả